Cellectis shifts CAR-T manufacturing in-house, boosts efficacy compared to third-party CDMOs: #ASH23 

Al­lo­gene­ic CAR-T biotech Cel­lec­tis took its CAR-T man­u­fac­tur­ing in-house af­ter fac­ing “bro­ken” sup­ply chain is­sues with third par­ty man­u­fac­tur­ers, and, ac­cord­ing to the com­pa­ny, the move boost­ed its ef­fi­ca­cy da­ta and ac­cel­er­at­ed its pro­duc­tion.

“It’s a strate­gic move; it’s not just fix­ing a bro­ken sup­ply chain. It’s al­so get­ting ready for what’s go­ing to make a big dif­fer­ence for us,” said David Sour­dive, Cel­lec­tis EVP of CMC and man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.